CAPR Capricor Therapeutics Inc

Price (delayed)

$8.67

Market cap

$504.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.45

Enterprise value

$574.18M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 3

Capricor Therapeutics, Inc. is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is ...

Highlights
CAPR's equity has soared by 135% year-on-year but it is down by 12% since the previous quarter
CAPR's quick ratio has soared by 67% YoY but it is down by 13% QoQ
Capricor Therapeutics's gross profit has shrunk by 100% YoY
CAPR's revenue has dropped by 100% year-on-year

Key stats

What are the main financial stats of CAPR

CAPR stock price

How has the Capricor Therapeutics stock price performed over time
Intraday
-7.17%
1 week
1.29%
1 month
37.84%
1 year
40.98%
YTD
-69.96%
QTD
-64%

Financial performance

How have Capricor Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$135.16M
Net income
-$129.42M
Gross margin
N/A
Net margin
N/A
Capricor Therapeutics's gross profit has shrunk by 100% YoY
CAPR's revenue has dropped by 100% year-on-year
Capricor Therapeutics's net income has shrunk by 85% YoY and by 13% QoQ
The operating income has dropped by 84% year-on-year and by 13% since the previous quarter

Price vs fundamentals

How does CAPR's price correlate with its fundamentals

Growth

What is Capricor Therapeutics's growth rate over time

Valuation

What is Capricor Therapeutics stock price valuation
P/E
N/A
P/B
2.04
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 54% year-on-year and by 6% since the previous quarter
CAPR's equity has soared by 135% year-on-year but it is down by 12% since the previous quarter
CAPR's P/B is 74% lower than its 5-year quarterly average of 8.6 and 56% lower than its last 4 quarters average of 5.0
CAPR's revenue has dropped by 100% year-on-year

Efficiency

How efficient is Capricor Therapeutics business performance
CAPR's ROIC is up by 36% from the previous quarter and by 20% YoY
The ROA has increased by 13% YoY and by 9% QoQ
The ROE has increased by 10% YoY and by 4.6% QoQ

Dividends

What is CAPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CAPR.

Financial health

How did Capricor Therapeutics financials performed over time
Capricor Therapeutics's total assets has surged by 176% YoY and by 13% QoQ
The company's total liabilities has surged by 157% QoQ
The debt is 63% smaller than the equity
CAPR's equity has soared by 135% year-on-year but it is down by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.